Does indomethacin reduce the risk of thromboembolic events in patients undergoing ERCP?

Gastrointest Endosc. 2024 May;99(5):862. doi: 10.1016/j.gie.2023.11.045.

Authors

Jinqing Wu¹, Hao Ding², Qiao Mei²

Affiliations

¹ Department of Gastroenterology, Fuyang People's Hospital, Fuyang, China.
² Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

PMID: 38649226
DOI: 10.1016/j.gie.2023.11.045

No abstract available

Publication types

Letter

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal* / adverse effects
Anti-Inflammatory Agents, Non-Steroidal* / therapeutic use
Cholangiopancreatography, Endoscopic Retrograde* / adverse effects
Humans
Indomethacin* / therapeutic use
Thromboembolism* / etiology
Thromboembolism* / prevention & control

Substances

Indomethacin
Anti-Inflammatory Agents, Non-Steroidal